Patent ID: 8980556
Filing Date: 2015-03-17
Classification: C12N,C12Q,C12Y

Abstract:
1. A method of determining a decreased likelihood of a response to EGFR antibody therapy of a cancer disease, the method comprising the steps of: a) isolating genomic DNA from a patient sample; b) amplifying a fragment of the KRAS gene in said DNA by means of PCR with a specific pair of amplification primers; c) determining that said amplified fragment comprises a mutation in the KRAS gene by means of a High Resolution Melting Analysis (HRM); and d) performing DNA sequencing to determine that the mutation is one of the mutations G13_VI4insG, V14A, or G60D in the KRAS gene, e) identifying the patient as less likely to respond to EGFR antibody therapy based on the presence of one or more of the mutations of step (d).